Legacy Pharma Solutions, a contract packager serving the global pharmaceutical industry with bottling, blistering, pouching, unit-of-use, serialization, compliance, and secondary packaging services, has promoted Brad Rayner to president.

A 17-year executive of the pharmaceutical industry, Rayner has played a pivotal role in the company’s recent market share growth and services expansion.

In his new role, Rayner’s overarching purview includes responsibility for all of Legacy Pharma Solutions’ sales, operations, quality control, and finances. Along with Dave Spence, the company’s chairman & majority owner, Rayner will set and execute a long-term sales strategy, define target markets and strategically position Legacy for continued growth.

“Brad has gained the respect of a significant number of organizations and industry professionals by consistently and effectively providing solutions to their pharmaceutical packaging needs,” said Spence. “His expertise and insight will continue to be invaluable during this period of service extension, and we look forward to many years of sustained success and growth under his leadership.”

In his previous role as EVP, sales & business development, Rayner was primarily focused on spearheading sales, marketing, and customer service teams. His stewardship of these efforts, combined with his deep operational knowledge and technical background, made him the ideal candidate to take the helm as president.

In recent years, Legacy Pharma Solutions has expanded beyond its contract packaging roots to provide offerings such as 3PL services, supply chain transparency solutions, and retail pharma product procurement for over-the-counter medications. To accommodate this as well as future growth, the company leased another 215,000-sq-ft open-space facility last spring near its St. Louis headquarters that nearly doubled its overall footprint, which now stands at over 500,000 sq ft. Legacy Pharma Solutions now employs more than 400.

Legacy will continue to build on its comprehensive turnkey services, and has plans to further expand capacity in 2021 by adding five more bottling and blister packaging lines in Q2 and Q3. The expansion-minded moves come amid recent growth in both the Rx and OTC sectors, and in expectation of continued heightened demand per the company’s transition into a high-volume, one-stop shop providing turnkey product packaging straight through market delivery.